TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10841179

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg) plus Vitamin D (800 IU)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Calcium (1200 mg)
Number of subjects: 148
Study: 8853667

Group type: EXPERIMENTAL
Intervention: Tylenol Extended Relief (ER APAP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immediate-release acetaminophen (IR APAP)
Number of subjects: 14
Study: 8422668

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (r‐hEPO) administration (3000 IU, 12 cases; 6000 IU, 14 cases), three times a week
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (r‐hEPO) administration
Number of subjects: 26
Study: 2873601

Group type: EXPERIMENTAL
Intervention: Fluperlapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 12
Study: 31291158

Group type: EXPERIMENTAL
Intervention: Anonymous BabyCenter.com loss support group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Closed Facebook loss group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 30453403

Group type: EXPERIMENTAL
Intervention: Bone dust collector
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 24525155

Group type: EXPERIMENTAL
Intervention: HTUPA (25 mg bolus)
Number of subjects: 221

Group type: COMPARATOR
Intervention: rt-PA (standard protocol)
Number of subjects: 221
Study: 22647414

Group type: COMPARATOR
Intervention: No anemia (n=712)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Mild anemia (n=141)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe anemia (n=160)
Number of subjects: 1013
Study: 20116842

Group type: EXPERIMENTAL
Intervention: No sedation (n=70 patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Interrupted sedation (20 mg/mL propofol for 48 h, 1 mg/mL midazolam thereafter) (n=70, control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: No sedation
Number of subjects: 140
Study: 17573510

Group type: EXPERIMENTAL
Intervention: Posaconazole 800 mg/d, administered in divided doses for 34 to 365 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Posaconazole treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Posaconazole treatment for >or= 12 months
Number of subjects: 15
Study: 15857324

Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12242060

Group type: EXPERIMENTAL
Intervention: Olanzapine (initiated at 2.5 mg/day, with increases allowed every 3 to 4 days up to a maximum of 15 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26135318

Group type: EXPERIMENTAL
Intervention: Indian F(ab')2 snake antivenom
Number of subjects: 75
Study: 8580279

Group type: EXPERIMENTAL
Intervention: Lintopride 0.1 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lintopride 0.3 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lintopride 0.5 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2571184

Group type: EXPERIMENTAL
Intervention: Secretin (0.05 CU kg‐1h‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatostatin (60 pmol kg‐1h‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Secretin and Somatostatin (combined infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Pentagastrin-stimulated acid secretion)
Number of subjects: 10
Study: 590601

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose)
Number of subjects: 100
Study: 31378318

Group type: EXPERIMENTAL
Intervention: Cefiderocol 2-g dose (therapeutic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefiderocol 4-g dose (supratherapeutic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400-mg oral dose
Number of subjects: 0
Study: 28784498

Group type: EXPERIMENTAL
Intervention: Repeated exposure to Brie, Gouda, and sharp Cheddar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated exposure to Emmental, Gorgonzola, and Parmigiano‐Reggiano
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual evaluation vs. social interaction
Number of subjects: 0
Study: 26055774

Group type: EXPERIMENTAL
Intervention: Function Focused Care Intervention for the Cognitively Impaired (FFC‐CI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 23052623

Group type: EXPERIMENTAL
Intervention: Starch-matrix beadlet (SMB, FloraGLO® Lutein 5 %)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cross-linked alginate-matrix beadlet (AMB, Lyc-O-Lutein 20 %)
Number of subjects: 48
Study: 22185023

Group type: EXPERIMENTAL
Intervention: Hyperuricemia (study group)
Number of subjects: 50
Study: 19856512

Group type: EXPERIMENTAL
Intervention: Chloroquine regimen group A (1200 mg total over 3 days: 600 mg on day 1, 300 mg on days 2 and 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chloroquine regimen group B (1500 mg total over 3 days: 750 mg on day 1, 375 mg on days 2 and 3)
Number of subjects: 48
Study: 16480348

Group type: EXPERIMENTAL
Intervention: Effect-site steered propofol patient-controlled sedation (PCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anaesthetist-administered propofol sedation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 15333431

Group type: EXPERIMENTAL
Intervention: EDLA (extended-duration local anesthetic) at concentrations of 6.25, 12.5, and 25 mg/mL
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aqueous bupivacaine (5.0 mg/mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EDLA (extended-duration local anesthetic)
Number of subjects: 18
Study: 11140434

Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 0.1 mg, twice daily for 4 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 1 mg, twice daily for 4 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 10 mg, twice daily for 4 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 days
Number of subjects: 21
Study: 9062598

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (15 ml of 0.5% bupivacaine injected twice)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (15 ml of 0.9% saline solution injected twice)
Number of subjects: 80
Study: 8282635

Group type: EXPERIMENTAL
Intervention: Maximal upright bicycle exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonexercise (control) day
Number of subjects: 10
Study: 3481331

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 or 400mg twice daily)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Doxycycline (100mg twice daily)
Number of subjects: 230
Study: 28784001

Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis with tablet nifedipine for 12 days or up to 34 weeks of gestation.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no maintenance tocolysis).
Number of subjects: 50
Study: 27832747

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 128
Study: 25010527

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (16-week program, 1 hour sessions, 3 times a week)
Number of subjects: 6
Study: 22067783

Group type: EXPERIMENTAL
Intervention: Mifepristone with ethacridine lactate
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Ethacridine lactate alone (Control)
Number of subjects: 1245
Study: 20352148

Group type: EXPERIMENTAL
Intervention: Comprehensive counselling
Number of subjects: 135

Group type: COMPARATOR
Intervention: Basic counselling
Number of subjects: 135
Study: 18234355

Group type: EXPERIMENTAL
Intervention: Paroxetine or citalopram treatment for 1 year
Number of subjects: 65
Study: 15681499

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 12859470

Group type: EXPERIMENTAL
Intervention: Cocaine 5%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Co-phenylcaine Forte (phenylephrine 0.5% and lidocaine 5%)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia using an atomiser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Larger diameter tubes
Number of subjects: 25
Study: 10375948

Group type: EXPERIMENTAL
Intervention: Active sarcoidosis
Number of subjects: 188

Group type: COMPARATOR
Intervention: Inactive sarcoidosis
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Active sarcoidosis treated with steroids
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Inactive sarcoidosis after corticotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Avian fanciers' lung exposed to antigen
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Avian fanciers' lung after a year interval in exposure to antigen
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Advanced idiopathic pulmonary fibrosis
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Moderate idiopathic pulmonary fibrosis
Number of subjects: 188

Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 188
Study: 9049974

Group type: EXPERIMENTAL
Intervention: P53 gene mutations in CML blast crisis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: P53 gene point mutations
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: P53 gene point mutation in extramedullary and bone marrow blast cells
Number of subjects: 27
Study: 2058006

Group type: EXPERIMENTAL
Intervention: Stool positive female patients
Number of subjects: 242

Group type: COMPARATOR
Intervention: Stool negative female patients
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Stool positive male patients
Number of subjects: 242

Group type: COMPARATOR
Intervention: Stool negative male patients
Number of subjects: 242
Study: 7076102

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (100 mg every 12 hours for two days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (160 mg and 800 mg respectively every 12 hours for two days)
Number of subjects: 100
Study: 31625419

Group type: EXPERIMENTAL
Intervention: Water exercise intervention (group A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Yoga exercise intervention (group C)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pilates exercise intervention (group B)
Number of subjects: 115
Study: 29481513

Group type: EXPERIMENTAL
Intervention: 1 jaw surgery group (30 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 2 jaw surgery group (22 patients)
Number of subjects: 52
Study: 27595687

Group type: EXPERIMENTAL
Intervention: CCTA in combination with CTP
Number of subjects: 600

Group type: COMPARATOR
Intervention: CCTA alone
Number of subjects: 600
Study: 24333646

Group type: EXPERIMENTAL
Intervention: Escapable stressor condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoked inescapable stressor condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no stress exposure)
Number of subjects: 0
Study: 22658147

Group type: EXPERIMENTAL
Intervention: ERN/LRPT + SIM
Number of subjects: 1398

Group type: COMPARATOR
Intervention: SIM alone
Number of subjects: 1398

Group type: COMPARATOR
Intervention: ERN/LRPT
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: ERN/LRPT + SIM for 12 weeks
Number of subjects: 1398
Study: 19711257

Group type: EXPERIMENTAL
Intervention: Intracisternal lysis with urokinase 120,000 IU/d for 48 hours followed by intrathecal nimodipine lavage for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 20
Study: 17669143

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study: 15498087

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg three times daily (TID)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg four times daily (QID)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study: 11450366

Group type: EXPERIMENTAL
Intervention: Gastroenterostomy
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Billroth II method
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 170
Study: 9572539

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 0.1% solution, 1 drop four times daily for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac tromethamine (KT) 0.5% solution, 1 drop four times daily for 14 days
Number of subjects: 60
Study: 8113776

Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) rehabilitation (27 hours of weekday treatment weekly)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Inpatient (INP) rehabilitation (48 hours of scheduled treatment weekly)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both groups (DH and INP)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) rehabilitation
Number of subjects: 111
Study: 2455331

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Carbachol (0.25 mg s.c.)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral Carbachol (6 or 12 mg/day for 2 weeks)
Number of subjects: 22
Study: 28994626

Group type: EXPERIMENTAL
Intervention: PRISM (MCPAP for Moms plus implementation assistance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MCPAP for Moms alone
Number of subjects: 30
Study: 26692579

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/day
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 24360928

Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use identified by routine screening (AUDIT-C)
Number of subjects: 63397
Study: 23530755

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 200
Study: 21498906

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5mg/day)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 302
Study: 18313597

Group type: EXPERIMENTAL
Intervention: SVC coil ON
Number of subjects: 113

Group type: COMPARATOR
Intervention: SVC coil OFF
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intercoil distance (17-cm vs 21-cm)
Number of subjects: 113
Study: 16325470

Group type: EXPERIMENTAL
Intervention: Low dose quinapril (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 12603413

Group type: EXPERIMENTAL
Intervention: High-grade PIN group
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 387
Study: 11127501

Group type: EXPERIMENTAL
Intervention: Cold air provocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anesthetizing the nose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaling an anti-cholinergic drug
Number of subjects: 0
Study: 8861087

Group type: EXPERIMENTAL
Intervention: Tibolone (Livial, 2.5 mg daily)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conjugated estrogens (Premarin, 0.625 mg daily) + Medrogestone (Colpron, 2 x 5 mg daily for 12 days each month)
Number of subjects: 129
Study: 1298968

Group type: EXPERIMENTAL
Intervention: Sulodexide (100 mg/die)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 30
Study: 6723531

Group type: EXPERIMENTAL
Intervention: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 50 X 10(6) E/m2 as 30-minute infusion on 5 consecutive days four-weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 20 X 10(6) E/m2 subcutaneously thrice weekly
Number of subjects: 12
Study: 31424491

Group type: EXPERIMENTAL
Intervention: Recombinant activated coagulation factor VII (rFVIIa) 80 μg/kg intravenous
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Recombinant activated coagulation factor VII (rFVIIa)
Number of subjects: 69
Study: 29439650

Group type: COMPARATOR
Intervention: ADPKD Outcomes Model (ADPKD-OM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline total kidney volume (TKV)
Number of subjects: 0
Study: 27189282

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (COX‐2i)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no COX‐2i)
Number of subjects: 69
Study: 25227833

Group type: EXPERIMENTAL
Intervention: Gemcitabine concomitant with nedaplatin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cisplatin concomitant with gemcitabine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Positive expression of ERCC1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Positive expression of RRM1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Positive expression of LRP
Number of subjects: 68
Study: 22307926

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine butylbromide
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination of paracetamol + hyoscine butylbromide
Number of subjects: 132

Group type: COMPARATOR
Intervention: Rescue analgesia
Number of subjects: 132
Study: 19942435

Group type: EXPERIMENTAL
Intervention: Three-dimensional gait analysis with a multi-segment foot model
Number of subjects: 18
Study: 17852629

Group type: EXPERIMENTAL
Intervention: 2.5% testosterone gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 32
Study: 16342345

Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 102

Group type: COMPARATOR
Intervention: DDDR pacing and antiarrhythmic drugs
Number of subjects: 102
Study: 11979157

Group type: COMPARATOR
Intervention: Light multidisciplinary treatment program
Number of subjects: 195

Group type: COMPARATOR
Intervention: Extensive multidisciplinary treatment program
Number of subjects: 195

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 195

Group type: COMPARATOR
Intervention: Light multidisciplinary treatment
Number of subjects: 195
Study: 9536408

Group type: EXPERIMENTAL
Intervention: Paraffin wax plus Acetulan in cetyl alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beeswax plus Acetulan in cetyl alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paraffin wax plus beeswax in cetyl alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetulan in cetyl alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paraffin wax in cetyl alcohol
Number of subjects: 10
Study: 8907133

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan 4 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1696310

Group type: EXPERIMENTAL
Intervention: CD34+ leukemia
Number of subjects: 795

Group type: COMPARATOR
Intervention: CD34- leukemia
Number of subjects: 795
Study: 356707

Group type: EXPERIMENTAL
Intervention: High-dose pentazocine (0.9 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 29878266

Group type: EXPERIMENTAL
Intervention: Whey protein (WHE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: α-lactalbumin-enriched whey protein (LAC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Casein (CAS)
Number of subjects: 10
Study: 28174052

Group type: EXPERIMENTAL
Intervention: Expedited transfer to a cardiac arrest centre (CAC) for goal-directed therapy including access to immediate reperfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Current standard of care involving delivery to the geographically closest hospital
Number of subjects: 40
Study: 26194186

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation plus perioperative ECF chemotherapy
Number of subjects: 752

Group type: COMPARATOR
Intervention: Perioperative ECF chemotherapy
Number of subjects: 752
Study: 23585314

Group type: EXPERIMENTAL
Intervention: Nomogram 1 (bolus of 80 U/Kg/h and initial infusion rate of 17 U/Kg/h)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nomogram 2 (bolus of 60 U/Kg, maximum of 4000 U, and initial infusion rate of 12 U/Kg/h, maximum of 900 U/h)
Number of subjects: 140
Study: 20061402

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon (IFN)‐alpha2a
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo plus interferon (IFN)‐alpha2a
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon (IFN)‐alpha2a (IRC analysis)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo plus interferon (IFN)‐alpha2a (IRC analysis)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon (IFN)‐alpha2b
Number of subjects: 649

Group type: COMPARATOR
Intervention: Interferon (IFN)‐alpha2b alone
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 649
Study: 18376260

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole once per day (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5 mg lansoprazole twice per day (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula (group C)
Number of subjects: 30